| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Neoplasm | 24 | 2024 | 332 | 3.140 |
Why?
|
| Ovarian Neoplasms | 15 | 2023 | 763 | 2.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2019 | 442 | 1.920 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2023 | 594 | 1.690 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2024 | 394 | 1.410 |
Why?
|
| Cancer Vaccines | 9 | 2014 | 160 | 1.060 |
Why?
|
| Epitopes, T-Lymphocyte | 6 | 2013 | 88 | 1.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 10 | 2024 | 319 | 1.040 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 1222 | 0.980 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2022 | 189 | 0.840 |
Why?
|
| Peptides | 4 | 2013 | 646 | 0.820 |
Why?
|
| Membrane Proteins | 14 | 2016 | 1215 | 0.800 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 205 | 0.740 |
Why?
|
| Th1 Cells | 12 | 2006 | 166 | 0.700 |
Why?
|
| Genetic Therapy | 2 | 2018 | 369 | 0.690 |
Why?
|
| Oleic Acids | 2 | 2023 | 26 | 0.680 |
Why?
|
| Neoplasms | 11 | 2023 | 3024 | 0.670 |
Why?
|
| Cell Engineering | 1 | 2018 | 5 | 0.630 |
Why?
|
| Gene Library | 1 | 2018 | 133 | 0.610 |
Why?
|
| Carboxymethylcellulose Sodium | 2 | 2013 | 8 | 0.560 |
Why?
|
| Polylysine | 2 | 2013 | 34 | 0.560 |
Why?
|
| Poly I-C | 2 | 2013 | 18 | 0.560 |
Why?
|
| Lymphocyte Activation | 8 | 2024 | 751 | 0.510 |
Why?
|
| Autoantigens | 2 | 2012 | 129 | 0.460 |
Why?
|
| Mannitol | 1 | 2013 | 50 | 0.450 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1429 | 0.440 |
Why?
|
| Vaccines, Subunit | 3 | 2012 | 55 | 0.430 |
Why?
|
| Interferon-gamma | 17 | 2015 | 451 | 0.430 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 540 | 0.410 |
Why?
|
| Antigens, CD | 2 | 2010 | 466 | 0.400 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 46 | 0.400 |
Why?
|
| Immunotherapy | 6 | 2022 | 666 | 0.400 |
Why?
|
| Mannose-Binding Lectins | 1 | 2010 | 6 | 0.380 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2022 | 56 | 0.380 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 86 | 0.360 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2021 | 275 | 0.360 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2015 | 135 | 0.340 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 289 | 0.340 |
Why?
|
| Immune Tolerance | 1 | 2011 | 337 | 0.320 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 131 | 0.310 |
Why?
|
| Humans | 41 | 2024 | 88946 | 0.300 |
Why?
|
| Mice | 24 | 2023 | 11724 | 0.290 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2024 | 215 | 0.290 |
Why?
|
| Antigen Presentation | 4 | 2013 | 215 | 0.280 |
Why?
|
| Female | 24 | 2023 | 45954 | 0.280 |
Why?
|
| Cells, Cultured | 10 | 2018 | 2880 | 0.270 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2551 | 0.260 |
Why?
|
| Dendritic Cells | 7 | 2010 | 440 | 0.260 |
Why?
|
| Immunologic Memory | 3 | 2022 | 162 | 0.250 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 40 | 0.250 |
Why?
|
| Cloning, Molecular | 3 | 2018 | 646 | 0.250 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 459 | 0.250 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2013 | 164 | 0.240 |
Why?
|
| Cytokines | 6 | 2012 | 801 | 0.230 |
Why?
|
| Retroelements | 1 | 2023 | 47 | 0.230 |
Why?
|
| Transduction, Genetic | 3 | 2018 | 160 | 0.220 |
Why?
|
| Mastocytoma | 1 | 2003 | 4 | 0.220 |
Why?
|
| Retroviridae | 3 | 2018 | 79 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2023 | 73 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 100 | 0.210 |
Why?
|
| Animals | 26 | 2023 | 27280 | 0.210 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.210 |
Why?
|
| Lymphoma | 2 | 2003 | 265 | 0.200 |
Why?
|
| Genetic Vectors | 2 | 2018 | 446 | 0.200 |
Why?
|
| Melanoma | 3 | 2024 | 467 | 0.200 |
Why?
|
| Receptors, CXCR6 | 1 | 2021 | 6 | 0.200 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 17 | 0.200 |
Why?
|
| Claudins | 1 | 2022 | 33 | 0.200 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 360 | 0.200 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 1573 | 0.190 |
Why?
|
| Repressor Proteins | 2 | 2021 | 423 | 0.190 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2021 | 16 | 0.190 |
Why?
|
| Th2 Cells | 5 | 2005 | 147 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 169 | 0.190 |
Why?
|
| Jurkat Cells | 2 | 2018 | 77 | 0.190 |
Why?
|
| Quinoxalines | 1 | 2021 | 50 | 0.190 |
Why?
|
| Mice, SCID | 2 | 2018 | 261 | 0.180 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 160 | 0.170 |
Why?
|
| Cross-Priming | 2 | 2010 | 48 | 0.170 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2013 | 305 | 0.160 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 2061 | 0.160 |
Why?
|
| Frozen Sections | 1 | 2018 | 49 | 0.150 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 195 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2010 | 565 | 0.150 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 3026 | 0.150 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 141 | 0.140 |
Why?
|
| Autoantibodies | 2 | 2023 | 268 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 374 | 0.140 |
Why?
|
| HLA-B44 Antigen | 1 | 2016 | 3 | 0.140 |
Why?
|
| HLA-B27 Antigen | 1 | 2016 | 8 | 0.140 |
Why?
|
| Streptococcus pyogenes | 2 | 2013 | 35 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 2 | 2009 | 168 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2015 | 699 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 886 | 0.130 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 463 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2024 | 3370 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1399 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2021 | 1533 | 0.130 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2010 | 43 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1265 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 1057 | 0.120 |
Why?
|
| Alphapapillomavirus | 1 | 2015 | 45 | 0.120 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 504 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2015 | 172 | 0.110 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 155 | 0.110 |
Why?
|
| CD40 Ligand | 1 | 2013 | 69 | 0.110 |
Why?
|
| Interleukin-4 | 5 | 2004 | 130 | 0.110 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2003 | 50 | 0.110 |
Why?
|
| Protein Binding | 2 | 2021 | 1485 | 0.110 |
Why?
|
| Bacterial Vaccines | 1 | 2012 | 42 | 0.100 |
Why?
|
| Leukemia | 2 | 2005 | 323 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 295 | 0.100 |
Why?
|
| Cytosol | 1 | 2012 | 192 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 106 | 0.100 |
Why?
|
| Endosomes | 1 | 2012 | 79 | 0.100 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 48 | 0.100 |
Why?
|
| Prognosis | 2 | 2021 | 3770 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2004 | 443 | 0.100 |
Why?
|
| Cell Differentiation | 6 | 2008 | 1521 | 0.090 |
Why?
|
| Immunity, Innate | 2 | 2004 | 429 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 39 | 0.090 |
Why?
|
| Clone Cells | 1 | 2010 | 214 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 557 | 0.090 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2023 | 12 | 0.090 |
Why?
|
| Immunization, Secondary | 1 | 2009 | 32 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 67 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1768 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 198 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 7 | 2006 | 1086 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2021 | 1990 | 0.080 |
Why?
|
| Immunity, Humoral | 3 | 2014 | 66 | 0.080 |
Why?
|
| Interleukin-2 | 3 | 2023 | 251 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 411 | 0.080 |
Why?
|
| Granzymes | 2 | 2022 | 94 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 6 | 2006 | 3204 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2752 | 0.080 |
Why?
|
| Lentivirus | 2 | 2005 | 43 | 0.080 |
Why?
|
| Aged | 6 | 2016 | 19044 | 0.080 |
Why?
|
| Salmonella typhimurium | 1 | 2007 | 32 | 0.080 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 262 | 0.070 |
Why?
|
| Middle Aged | 7 | 2016 | 25826 | 0.070 |
Why?
|
| Chemokines, CC | 2 | 2004 | 36 | 0.070 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2004 | 77 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2005 | 170 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 6767 | 0.070 |
Why?
|
| Cell Line | 1 | 2010 | 2495 | 0.070 |
Why?
|
| Killer Cells, Natural | 2 | 2004 | 275 | 0.070 |
Why?
|
| Adult | 6 | 2014 | 26473 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2008 | 605 | 0.060 |
Why?
|
| HLA-A24 Antigen | 1 | 2005 | 19 | 0.060 |
Why?
|
| WT1 Proteins | 1 | 2005 | 20 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2008 | 439 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2022 | 2011 | 0.060 |
Why?
|
| Hormones | 1 | 2005 | 139 | 0.060 |
Why?
|
| MART-1 Antigen | 1 | 2024 | 21 | 0.060 |
Why?
|
| Galactosylceramides | 1 | 2004 | 8 | 0.060 |
Why?
|
| Cell Survival | 2 | 2019 | 981 | 0.060 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2024 | 32 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2005 | 115 | 0.060 |
Why?
|
| Stem Cells | 2 | 2023 | 372 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2024 | 97 | 0.060 |
Why?
|
| Graft vs Host Reaction | 1 | 2004 | 15 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2004 | 92 | 0.060 |
Why?
|
| CpG Islands | 1 | 2004 | 157 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2004 | 84 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 397 | 0.060 |
Why?
|
| Receptor, trkC | 1 | 2003 | 2 | 0.060 |
Why?
|
| Neurotrophin 3 | 1 | 2003 | 3 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 178 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.060 |
Why?
|
| Integrin alpha2beta1 | 1 | 2003 | 1 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 32 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 250 | 0.060 |
Why?
|
| Ovalbumin | 4 | 2004 | 109 | 0.060 |
Why?
|
| Neutrophils | 2 | 2003 | 308 | 0.060 |
Why?
|
| Vitamin D | 1 | 2006 | 268 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 996 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 108 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 144 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2550 | 0.060 |
Why?
|
| Cattle | 1 | 2023 | 375 | 0.050 |
Why?
|
| Galectin 3 | 1 | 2023 | 17 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 249 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2021 | 657 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 274 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2004 | 158 | 0.050 |
Why?
|
| Time Factors | 2 | 2009 | 5318 | 0.050 |
Why?
|
| Peptide Fragments | 3 | 2013 | 461 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 6280 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 68 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 887 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 92 | 0.050 |
Why?
|
| Leukocytosis | 1 | 2001 | 16 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2001 | 22 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2013 | 36 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 992 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2350 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 1113 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 680 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 199 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 268 | 0.040 |
Why?
|
| Mutation | 1 | 2011 | 4126 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 299 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 232 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2012 | 261 | 0.040 |
Why?
|
| Interleukin-12 | 2 | 2013 | 109 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 329 | 0.040 |
Why?
|
| Lung | 2 | 2004 | 1258 | 0.040 |
Why?
|
| Male | 4 | 2021 | 42191 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 1114 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 1754 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 1974 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1999 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1241 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 2345 | 0.030 |
Why?
|
| Asthma | 1 | 2004 | 976 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2016 | 84 | 0.030 |
Why?
|
| Chemokine CCL11 | 2 | 2004 | 11 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 2 | 2004 | 28 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 370 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 308 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2013 | 8 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 2014 | 15 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 637 | 0.030 |
Why?
|
| Lymphocyte Depletion | 2 | 2004 | 98 | 0.030 |
Why?
|
| Perforin | 1 | 2013 | 55 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2013 | 61 | 0.030 |
Why?
|
| CD3 Complex | 2 | 2003 | 134 | 0.030 |
Why?
|
| Picibanil | 1 | 2013 | 2 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 14 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 138 | 0.030 |
Why?
|
| Interferon-beta | 2 | 2006 | 126 | 0.030 |
Why?
|
| Azacitidine | 1 | 2014 | 139 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 75 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2013 | 83 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2004 | 124 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 298 | 0.030 |
Why?
|
| Serratia marcescens | 1 | 2012 | 5 | 0.030 |
Why?
|
| Spleen | 2 | 2004 | 431 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 124 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 81 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2006 | 1128 | 0.030 |
Why?
|
| Body Temperature | 1 | 2012 | 124 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 859 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2003 | 690 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 358 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 353 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2014 | 8188 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1796 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1484 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1649 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1310 | 0.020 |
Why?
|
| Coated Vesicles | 1 | 2008 | 4 | 0.020 |
Why?
|
| Amination | 1 | 2008 | 5 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2008 | 20 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 76 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 118 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2008 | 145 | 0.020 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2007 | 4 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2007 | 12 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 90 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1361 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 113 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2008 | 260 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 421 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2006 | 53 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 112 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3655 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2006 | 425 | 0.020 |
Why?
|
| Mucus | 1 | 2004 | 19 | 0.020 |
Why?
|
| Liposomes | 1 | 2004 | 93 | 0.020 |
Why?
|
| Genes, abl | 1 | 2004 | 12 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2004 | 136 | 0.010 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2004 | 7 | 0.010 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2004 | 20 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2004 | 40 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 147 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 258 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 308 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2003 | 18 | 0.010 |
Why?
|
| Tyrosine | 1 | 2004 | 133 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2003 | 37 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 354 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 392 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 443 | 0.010 |
Why?
|
| Immunization | 1 | 2003 | 160 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2014 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 105 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2003 | 182 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1011 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 794 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 519 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 10 | 0.010 |
Why?
|
| Aerosols | 1 | 2001 | 44 | 0.010 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2001 | 41 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2001 | 190 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 755 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2004 | 490 | 0.010 |
Why?
|
| Eosinophils | 1 | 2001 | 194 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 975 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1939 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 1884 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 738 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 970 | 0.010 |
Why?
|